SCHEMBL24253533

SCHEMBL24253533

O=C1CCCC2(CCN(c3ncc(-c4ccc(F)cc4)o3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
RAD51 Q06609 1/20 0.34
SPR P35270 1/20 0.33
MMP13 P45452 1/20 0.33
CYP11B2 P19099 1/20 0.32
PRKDC P78527 1/20 0.31
AOC3 Q16853 1/20 0.31
TNKS O95271 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
TNKS2 Q9H2K2 1/20 0.30
HCRTR1 O43613 3/20 0.30
HCRTR2 O43614 3/20 0.30
KCNH2 Q12809 1/20 0.30
LTC4S Q16873 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424161 1.00 LMNA (0.35) LMNATP53MAPTRAD51SPR
SCHEMBL24253721 0.82 RAD51 (0.32) RAD51CYP11B2HCRTR1HCRTR2KCNH2
SCHEMBL30423878 0.82 RAD51 (0.32) RAD51CYP11B2HCRTR1HCRTR2KCNH2
SCHEMBL30424244 0.79 CYP11B2 (0.35) RAD51MMP13CYP11B2
SCHEMBL24253617 0.79 CYP11B2 (0.35) RAD51MMP13CYP11B2
SCHEMBL24253729 0.78 HCRTR1 (0.49) LMNATP53RAD51HCRTR1HCRTR2
SCHEMBL30423954 0.78 HCRTR1 (0.49) LMNATP53RAD51HCRTR1HCRTR2
SCHEMBL24253724 0.78 HCRTR1 (0.33) MAPTRAD51MMP13CYP11B2CYP2C9
SCHEMBL30424476 0.78 HCRTR1 (0.33) MAPTRAD51MMP13CYP11B2CYP2C9
SCHEMBL24253930 0.77 GRM5 (0.33) RAD51MMP13CYP11B2HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 LMNA 2975/4885TP53 3877/4885MAPT 4450/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 LMNA 2975/4885TP53 3877/4885MAPT 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.